PERFORM Centre, Concordia University, Montreal, Québec, Canada
Department of Mathematics and Statistics, Concordia University, Montreal, Québec, Canada.
BMJ Open. 2022 Jun 15;12(6):e058857. doi: 10.1136/bmjopen-2021-058857.
Severe obesity (SO) prevalence varies between reference curve-based definitions (WHO: ≥99th percentile, Centers for Disease Control and Prevention (CDC): >1.2×95th percentile). Whether SO definitions differentially predict cardiometabolic disease risk is critical for proper clinical care and management but is unknown.
Prospective cohort study SETTING: SO definitions were applied at baseline (2005-2008, M=9.6 years, n=548), and outcomes (fasting lipids, glucose, homoeostatic model assessment (HOMA-IR) and blood pressure) were assessed at first follow-up (F1: 2008-2011, M=11.6 years) and second follow-up (2015-2017, M=16.8 years) of the Quebec Adipose and Lifestyle Investigation in Youth cohort in Montreal, Quebec.
Respondents were youth who had at least one biological parent with obesity.
Unfavourable cardiometabolic levels of fasting blood glucose (≥6.1 mmol/L), insulin resistance (HOMA-IR index ≥2.0), high-density lipoprotein <1.03 mmol/L, low-density lipoprotein ≥2.6 mmol/L and triglycerides 1.24 mmol/L. Unfavourable blood pressure was defined as ≥90th percentile for age-adjusted, sex-adjusted and height-adjusted systolic or diastolic blood pressure.
Area under the receiver operating characteristic curve (AUC) and McFadden psuedo R for predicting F1 or F2 unfavourable cardiometabolic levels from baseline SO definitions were calculated. Agreement was assessed with kappas.
Baseline SO prevalence differed (WHO: 18%, CDC: 6.7%). AUCs ranged from 0.52 to 0.77, with fair agreement (kappa=37%-55%). WHO-SO AUCs for detecting unfavourable HOMA-IR (AUC>0.67) and high-density lipoprotein (AUC>0.59) at F1 were statistically superior than CDC-SO (AUC>0.59 and 0.53, respectively; p<0.05). Only HOMA-IR and the presence of more than three risk factors had acceptable model fit. WHO-SO was not more predictive than WHO-obesity, but CDC-SO was statistically inferior to CDC-obesity.
WHO-SO is statistically superior at predicting cardiometabolic risk than CDC-SO. However, as most AUCs were generally uninformative, and obesity definitions were the same if not better than SO, the improvement may not be clinically meaningful.
严重肥胖症(SO)的患病率因参考曲线定义的不同而有所差异(世界卫生组织[WHO]:≥第 99 百分位,疾病控制与预防中心[CDC]:>第 1.2 倍 95 百分位)。因此,明确 SO 定义是否会对心血管代谢疾病风险产生不同的预测作用,对于正确的临床护理和管理至关重要,但目前尚不清楚。
前瞻性队列研究
在魁北克青少年脂肪和生活方式调查队列的蒙特利尔(Quebec)研究中,SO 定义于基线(2005-2008 年,M=9.6 岁,n=548)时应用,并且在第一次随访(F1:2008-2011 年,M=11.6 岁)和第二次随访(2015-2017 年,M=16.8 岁)时评估空腹血脂、葡萄糖、稳态模型评估(HOMA-IR)和血压等结局。
受访者是至少有一位肥胖父母的年轻人。
空腹血糖(≥6.1mmol/L)、胰岛素抵抗(HOMA-IR 指数≥2.0)、高密度脂蛋白<1.03mmol/L、低密度脂蛋白≥2.6mmol/L 和甘油三酯 1.24mmol/L 等不良心血管代谢水平。定义血压不良为年龄、性别和身高校正后的收缩压或舒张压≥第 90 百分位。
计算基线 SO 定义预测 F1 或 F2 不良心血管代谢水平的受试者工作特征曲线(ROC)下面积(AUC)和麦克法登伪 R 值。采用卡帕值评估一致性。
基线 SO 的患病率不同(WHO:18%,CDC:6.7%)。AUC 范围为 0.52 至 0.77,具有适度的一致性(卡帕=37%-55%)。与 CDC-SO(AUC>0.59 和 0.53)相比,WHO-SO 对检测 F1 不良 HOMA-IR(AUC>0.67)和高密度脂蛋白(AUC>0.59)的 AUC 具有统计学优势(p<0.05)。只有 HOMA-IR 和存在超过三种危险因素的模型拟合较好。WHO-SO 并不比 WHO 肥胖具有更好的预测性,但 CDC-SO 在统计学上劣于 CDC 肥胖。
与 CDC-SO 相比,WHO-SO 在预测心血管代谢风险方面具有统计学优势。然而,由于大多数 AUC 通常没有信息,并且肥胖定义与 SO 相同或更好,因此这种改善可能在临床上没有意义。